How Can We Boost Colorectal and Hepatocellular Cancer Screening Among Underserved Populations?

Current Gastroenterology Reports

Volumn 17, Issue 6, 2015, Pages

  Goebel, Melissa ^a   Singal, Amit G ^b   Nodora, Jesse ^a,c   Castañeda, Sheila F ^d   Martinez, Elena ^a,c   Doubeni, Chyke ^e   Laiyemo, Adeyinka ^f   Gupta, Samir ^a,g  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d SAN DIEGO STATE UNIVERSITY   (United States)

^e UNIVERSITY OF PENNSYLVANIA   (United States)

^f HOWARD UNIVERSITY COLLEGE OF MEDICINE   (United States)

^g VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

Author keywords

cancer disparities; Colorectal cancer screening; Hepatocellular carcinoma screening

Indexed keywords

AGE; CANCER INCIDENCE; CANCER MORTALITY; CANCER SCREENING; CANCER STAGING; CANCER SURVIVAL; COLONOSCOPY; COLORECTAL CANCER; CULTURAL FACTOR; EARLY DIAGNOSIS; EDUCATIONAL STATUS; HEALTH CARE DISPARITY; HEALTH INSURANCE; HEPATITIS B; HIGH RISK PATIENT; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MEDICALLY UNDERSERVED; OCCULT BLOOD TEST; PATIENT EDUCATION; PATIENT PARTICIPATION; RACE DIFFERENCE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIGMOIDOSCOPY; SOCIAL STATUS; SURVIVAL RATE; SURVIVAL TIME; UNITED STATES; CARCINOMA, HEPATOCELLULAR; COLORECTAL NEOPLASMS; EARLY CANCER DIAGNOSIS; FEMALE; LIVER NEOPLASMS; MALE; PROCEDURES; STATISTICS AND NUMERICAL DATA; VULNERABLE POPULATION;

CARCINOMA, HEPATOCELLULAR; COLORECTAL NEOPLASMS; EARLY DETECTION OF CANCER; FEMALE; HEALTHCARE DISPARITIES; HUMANS; LIVER NEOPLASMS; MALE; UNITED STATES; VULNERABLE POPULATIONS;

EID: 84930670380     PISSN: 15228037     EISSN: 1534312X     Source Type: Journal    
DOI: 10.1007/s11894-015-0445-1     Document Type: Review

References (59)

1. Surveillance E and end results program. Fast Stats. In. 04/2014 ed; 2014.
2. Doubeni CA, Laiyemo AO, Major JM, et al. Socioeconomic status and the risk of colorectal cancer: an analysis of more than a half million adults in the National Institutes of Health-AARP Diet and Health Study. Cancer. 2012;118:3636–44. Observational study that highlights the relationship of socioeconomic status to risk for colorectal cancer using a very large sample.
3. Steinbrecher A, Fish K, Clarke CA, et al. Examining the association between socioeconomic status and invasive colorectal cancer incidence and mortality in California. Cancer Epidemiol Biomarkers Prev Publ Am Assoc Cancer Res Cosponsored Am Soc Prevent Oncol. 2012;21:1814–22.
4. Halpern MT, Ward EM, Pavluck AL, et al. Association of insurance status and ethnicity with cancer stage at diagnosis for 12 cancer sites: a retrospective analysis. Lancet Oncol. 2008;9:222–31.
5. Clegg LX, Reichman ME, Miller BA, et al. Impact of socioeconomic status on cancer incidence and stage at diagnosis: selected findings from the surveillance, epidemiology, and end results: National Longitudinal Mortality Study. Cancer Causes Control CCC. 2009;20:417–35.
6. DeSantis C, Naishadham D, Jemal A. Cancer statistics for African Americans, 2013. CA Cancer J Clin. 2013;63:151–66. Comprehensive review of cancer statistics for African-Americans.
7. Howlader NNA, Krapcho M, Neyman N, Aminou R, Waldron W, Altekruse SF, et al. SEER Cancer Statistics Review, 1975–2009 (Vintage 2009 Populations), National Cancer Institute. In. Bethesda, 2012.
8. Institute NC. Colorectal cancer stage distribution (SEER Summary Stage 2000) for non-Hispanic whites vs. Hispanics, all ages, both sexes, 2000–2010. In
9. Lee W, Nelson R, Mailey B, et al. Socioeconomic factors impact colon cancer outcomes in diverse patient populations. J Gastrointestinal Surg Off J Soc Surg Aliment Tract. 2012;16:692–704.
10. Ward E, Halpern M, Schrag N, et al. Association of insurance with cancer care utilization and outcomes. CA Cancer J Clin. 2008;58:9–31.
11. Siegel R, Ma J, Zou Z, et al. Cancer statistics, 2014. CA Cancer J Clin. 2014;64:9–29.
12. El-Serag HB, Kramer J, Duan Z, et al. Racial differences in the progression to cirrhosis and hepatocellular carcinoma in HCV-infected veterans. Am J Gastroenterol. 2014;109:1427–35.
13. Shebl FM, Capo-Ramos DE, Graubard BI, et al. Socioeconomic status and hepatocellular carcinoma in the United States. Cancer Epidemiol Biomarkers Prevent Publ Am Assoc Cancer Res Cosponsored Am Soc Prevent Oncol. 2012;21:1330–5.
14. Artinyan A, Mailey B, Sanchez-Luege N, et al. Race, ethnicity, and socioeconomic status influence the survival of patients with hepatocellular carcinoma in the United States. Cancer. 2010;116:1367–77.
15. Singal AG, Li X, Tiro J, et al. Racial, social, and clinical determinants of hepatocellular carcinoma surveillance. Am J Med. 2014. doi:10.1016/j.amjmed.2014.07.027:.
16. Sloane D, Chen H, Howell C. Racial disparity in primary hepatocellular carcinoma: tumor stage at presentation, surgical treatment and survival. J Natl Med Assoc. 2006;98:1934–9.
17. Davila JA, El-Serag HB. Racial differences in survival of hepatocellular carcinoma in the United States: a population-based study. Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc. 2006;4:104–10. quiz 104–105.
18. Singal AG, Yopp A, et al. Utilization of hepatocellular carcinoma surveillance among American patients: a systematic review. J Gen Intern Med. 2012;27:861–7.
19. Tan D, Yopp A, Beg MS, et al. Meta-analysis: underutilisation and disparities of treatment among patients with hepatocellular carcinoma in the United States. Aliment Pharmacol Ther. 2013;38:703–12.
20. Mathur AK, Osborne NH, Lynch RJ, et al. Racial/ethnic disparities in access to care and survival for patients with early-stage hepatocellular carcinoma. Arch Surg (Chicago, Ill 1960). 2010;145:1158–63.
21. Shah SA, Smith JK, Li Y, et al. Underutilization of therapy for hepatocellular carcinoma in the medicare population. Cancer. 2011;117:1019–26.
22. Yu JC, Neugut AI, Wang S, et al. Racial and insurance disparities in the receipt of transplant among patients with hepatocellular carcinoma. Cancer. 2010;116:1801–9.
23. Zak Y, Rhoads KF, Visser BC. Predictors of surgical intervention for hepatocellular carcinoma: race, socioeconomic status, and hospital type. Arch Surg (Chicago Ill 1960). 2011;146:778–84.
24. Force USPST. Screening for colorectal cancer. In. 05/2007 ed. Topic Page; 2008.
25. Edwards BK, Ward E, Kohler BA, et al. Annual report to the nation on the status of cancer, 1975–2006, featuring colorectal cancer trends and impact of interventions (risk factors, screening, and treatment) to reduce future rates. Cancer. 2010;116:544–73.
26. Society AC. Cancer prevention & early detection facts & figures. In 2013.
27. Brown ML, Klabunde CN, Cronin KA, et al. Challenges in meeting healthy people 2020 objectives for cancer-related preventive services, national health interview survey, 2008 and 2010. Prevent Chron Dis. 2014;11:E29.
28. Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology (Baltimore, Md). 2005;42:1208–36.
29. Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology (Baltimore, Md). 2011;53:1020–2.
30. Sherman M, Bruix J. Screening for liver cancer: the rush to judgment. Ann Intern Med. 2012;157:300–1. author reply 301–302.
31. Lederle FA, Pocha C. Screening for liver cancer: the rush to judgment. Ann Intern Med. 2012;156:387–9.
32. Zhang BH, Yang BH, Tang ZY. Randomized controlled trial of screening for hepatocellular carcinoma. J Cancer Res Clin Oncol. 2004;130:417–22.
33. Singal AG, Pillai A, Tiro J. Early detection, curative treatment, and survival rates for hepatocellular carcinoma surveillance in patients with cirrhosis: a meta-analysis. PLoS Med. 2014;11:e1001624. Key meta-analysis examining potential impact of surveillance for HCC on outcomes.
34. Tian C, Singal AG. Clinical reminders for hepatocellular carcinoma surveillance: an early step in a longjourney. Clin Gastroenterol Hepatol. 2015;13(1):180–2.
35. Singal AG, Yopp AC, Gupta S, et al. Failure rates in the hepatocellular carcinoma surveillance process. Cancer Prevent Res (Philadelphia, Pa). 2012;5:1124–30.
36. Singal AG, Marrero JA. Recent advances in the treatment of hepatocellular carcinoma. Curr Opin Gastroenterol. 2010;26:189–95.
37. Dalton-Fitzgerald E, Tiro J, Kandunoori P, et al. Practice patterns and attitudes of primary care providers and barriers to surveillance of hepatocellular carcinoma in patients with cirrhosis. Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc. 2014. doi:10.1016/j.cgh.2014.06.031:.
38. Singal AG, Volk ML, Rakoski MO, et al. Patient involvement in healthcare is associated with higher rates of surveillance for hepatocellular carcinoma. J Clin Gastroenterol. 2011;45:727–32.
39. Gupta S, Sussman DA, Doubeni CA, et al. Challenges and possible solutions to colorectal cancer screening for the underserved. J Natl Cancer Inst. 2014;106:dju032. Detailed review of challenges to screening underserved populations for CRC. Includes research and policy recommendations, as well as a model to consider when designing research and policy recommendations.
40. Levin TR, Jamieson L, Burley DA, et al. Organized colorectal cancer screening in integrated health care systems. Epidemiol Rev. 2011;33:101–10. Authoritative review of of the differences between outreach and inreach strategies for boosting colorectal cancer screening.
41. Baker DW, Brown T, Buchanan DR, et al. Comparative effectiveness of a multifaceted intervention to improve adherence to annual colorectal cancer screening in community health centers: a randomized clinical trial. JAMA Int Med. 2014;174:1235–41. Randomized trial in a community health center setting demonstrating that high rates of repeat fecal immunochemical test screening can be achieved with outreach interventions.
42. Jean-Jacques M, Kaleba EO, Gatta JL, et al. Program to improve colorectal cancer screening in a low-income, racially diverse population: a randomized controlled trial. Ann Fam Med. 2012;10:412–7.
43. Coronado GD, Golovaty I, Longton G, et al. Effectiveness of a clinic-based colorectal cancer screening promotion program for underserved Hispanics. Cancer. 2011;117:1745–54.
44. Davila JA, Morgan RO, Richardson PA, et al. Use of surveillance for hepatocellular carcinoma among patients with cirrhosis in the United States. Hepatology (Baltimore, Md). 2010;52:132–41.
45. Holt CL, Litaker MS, Scarinci IC, et al. Spiritually based intervention to increase colorectal cancer screening among African Americans: screening and theory-based outcomes from a randomized trial. Health Educ Behav Off Publ Soc Publ Health Educ. 2013;40:458–68.
46. Larkey LK, Herman PM, Roe DJ, et al. A cancer screening intervention for underserved Latina women by lay educators. J Women’s Health. 2012;21:557–66.
47. Anonymous. Vital signs: colorectal cancer screening test use—United States, 2012. MMWR Morb Mortal Wkly Rep. 2013;62:881–8.
48. Jerant A, Kravitz RL, Sohler N, et al. Sociopsychological tailoring to address colorectal cancer screening disparities: a randomized controlled trial. Ann Fam Med. 2014;12:204–14.
49. Raich PC, Whitley EM, Thorland W, et al. Patient navigation improves cancer diagnostic resolution: an individually randomized clinical trial in an underserved population. Cancer Epidemiol Biomarkers Prevent Publ Am Assoc Cancer Res Cosponsored Am Soc Prevent Oncol. 2012;21:1629–38.
50. Katz ML, Fisher JL, Fleming K, et al. Patient activation increases colorectal cancer screening rates: a randomized trial among low-income minority patients. Cancer Epidemiol Biomarkers Prevent Publ Am Assoc Cancer Res Cosponsored Am Soc Prevent Oncol. 2012;21:45–52.
51. Lasser KE, Murillo J, Lisboa S, et al. Colorectal cancer screening among ethnically diverse, low-income patients: a randomized controlled trial. Arch Intern Med. 2011;171:906–12.
52. Gupta S, Halm EA, Rockey DC, et al. Comparative effectiveness of fecal immunochemical test outreach, colonoscopy outreach, and usual care for boosting colorectal cancer screening among the underserved: a randomized clinical trial. JAMA Int Med. 2013;173:1725–32. Randomized trial demonstrating that outreach offering FIT is much more effective than outreach offering colonoscopy for one time screening completion.
53. Inadomi JM, Vijan S, Janz NK, et al. Adherence to colorectal cancer screening: a randomized clinical trial of competing strategies. Arch Intern Med. 2012;172:575–82.
54. Potter MB, Walsh JM, Yu TM, et al. The effectiveness of the FLU-FOBT program in primary care a randomized trial. Am J Prev Med. 2011;41:9–16. Randomized trial showing a simple offer of FOBT at time of flu vaccination by nurses and medical assistants can boost CRC screening.
55. Sabatino SA, Lawrence B, Elder R, et al. Effectiveness of interventions to increase screening for breast, cervical, and colorectal cancers: nine updated systematic reviews for the guide to community preventive services. Am J Prev Med. 2012;43:97–118.
56. Beste LA, Ioannou GN, Yang Y, et al. Improved surveillance for hepatocellular carcinoma with a primary care-oriented clinical reminder. Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc. 2014. doi:10.1016/j.cgh.2014.04.033:.
57. Wigg AJ, McCormick R, Wundke R, et al. Efficacy of a chronic disease management model for patients with chronic liver failure. Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc. 2013;11:850–8. e851-854.
58. Aberra FB, Essenmacher M, Fisher N, et al. Quality improvement measures lead to higher surveillance rates for hepatocellular carcinoma in patients with cirrhosis. Dig Dis Sci. 2013;58:1157–60.
59. Singal AG, Tiro JA, Gupta S. Improving hepatocellular carcinoma screening: applying lessons from colorectal cancer screening. Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc. 2013;11:472–7.